Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report - Scorecard - MDSpire

Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

  • By

  • Fang Yang

  • Linli Xuan

  • Jun Li

  • May 25, 2026

  • 0 min

Share

Clinical Scorecard: Severe Immune-Mediated Inflammatory Response Dominated by IL-6 and Possible Arginine Vasopressin Deficiency Following Ivonescimab Treatment in Advanced EGFR-Mutant Lung Squamous Cell Carcinoma: A Case Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care Setting

Key Highlights

    Guideline-Based Recommendations

    Diagnosis

      Management

        Monitoring & Follow-up

          Risks

            Patient & Prescribing Data

            Clinical Best Practices

              Related Resources & Content

              Original Source(s)

              Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report

              • by Fang Yang, Linli Xuan, Jun Li

              • May 25, 2026

              Related Content

              Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review

              The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities

              Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma